There are probably around a mere dozen or so oncology focused companies developing new masking technologies relating to protease cleavable linkers for antibodies, bispecifics, and antibody drug conjugates (ADCs).
Why might this strategy be useful and what are the means for achieving it?
In our latest expert interview, we focus on one player in this niche to explore their approach, look at what they are doing, and think about where they might be headed in the future in terms of new product development and a novel oncology pipeline.
Will the techniques learned in the oncology arena have utility in other therapy areas as well? After all, let’s not forget for every antagonist there is an agonistic effect applicable elsewhere…